Ποια είναι η τιμή για Marinus Pharmaceuticals, Inc. (MRNS)

Η τιμή για Marinus Pharmaceuticals, Inc. (MRNS) είναι $0.55

Ποια είναι η κεφαλαιοποίηση αγοράς για Marinus Pharmaceuticals, Inc. (MRNS)

Η κεφαλαιοποίηση αγοράς για Marinus Pharmaceuticals, Inc. (MRNS) είναι $28.90M

Marinus Pharmaceuticals, Inc. (MRNS) Διαίρεση Μετοχών

Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.